CytRx's (CYTR) Tumor-Targeted Doxorubicin Conjugate Delivers Doxorubcin Safely at Higher Doese
Tweet Send to a Friend
CytRx Corporation (Nasdaq: CYTR) today announced that its tumor-targeted doxorubicin conjugate INNO-206 is delivering doxorubicin safely at doses ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
